cellvie Information

cellvie is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation was developed by cellvie's co-founder, Dr. James McCully at Harvard Medical School and the company was founded to take this technology from bench to bed. We believe in mitochondria as a platform technology. In the first applicaiton, we are seeking to leverage the efficient cellular uptake and endosomal release capabilities of these organelles to deliver genetic medicines. What makes mitochondria unique as a delivery system are their size, and thus unmatched carrying capacity, their non-viral nature and hence the possibility to be repeatedly dosed, and their inherent therapeutic potential, which may bring benefit beyond the payload (depending on the indication). We are developing mitochondria-enabled gene therapy for the treatment of Epidermolysis Bullosa (EB) as the first indication. EB is a debilitating genetic orphan disease. Patients suffer from fragile skin, chronic wounds, pain, infections, and complications of internal tissues. With even the slightest touch having the potential to cause the skin to tear, the every day life of EB patients is severly compromised. At cellvie, we are striving to improve patients' lives by developing a topical gene therapy to correct the molecular defect. This shall enable wounds to close, to stay closed for longer, and relieve patients of the painful wound burden.